Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: HRMY stock price vs ECL: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ECL's multiple
Needs ECL P/E.
Implied fair value · at HRMY's multiple
Needs HRMY P/E.
Live quote
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: HRMY FY 2025 (ended Dec 31, 2025) · ECL FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
HARMONY BIOSCIENCES HOLDINGS, INC. · implied price per share
Bear
$42.25
Base
$49.71
Bull
$57.16
ECOLAB INC. · implied price per share
Bear
$75.06
Base
$88.31
Bull
$101.55
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.19x
0.83x
Net debt / EBITDA
Leverage against operating earnings
-2.20x
1.82x
Cash and equivalents
Liquid reserves on the balance sheet
$775.34M
$646.20M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Jazz Pharmaceuticals plc
HRMY vs JAZZ
SUPERNUS PHARMACEUTICALS, INC.
HRMY vs SUPN
Intra-Cellular Therapies, Inc.
HRMY vs ITCI
ACADIA PHARMACEUTICALS INC
HRMY vs ACAD
Vanda Pharmaceuticals Inc.
HRMY vs VNDA
LivaNova PLC
HRMY vs LIVN
Procter & Gamble Company
HRMY vs PG
COLGATE PALMOLIVE CO
HRMY vs CL
CLOROX CO /DE/
HRMY vs CLX
KIMBERLY CLARK CORP
HRMY vs KMB
$163.66M
$8.13B
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe HRMY can sustain its 21.5% revenue growth and high-margin profile, then favor HRMY over ECL because the stock is priced at a steep discount on P/E, P/S, and EV/EBITDA despite stronger operating metrics; if you prefer a valuation anchored to the provided historical and DCF ranges, the upside case is much less dramatic.
HRMY trades at 13.7x P/E, 2.5x P/S, and 5.6x EV/EBITDA versus ECL at 38.9x, 5.0x, and 21.2x, indicating a large discount despite superior reported growth and profitability. The stated implied price of $105.48 versus the current $37.26 suggests 183.1% upside, but that gap should be viewed against the historical band and DCF range, which are much closer to the current price.
Supporting Metrics
